PT - JOURNAL ARTICLE AU - Guglielmetti, Lorenzo AU - Jaspard, Marie AU - Le Dû, Damien AU - Lachâtre, Marie AU - Marigot-Outtandy, Dhiba AU - Bernard, Christine AU - Veziris, Nicolas AU - Robert, Jérôme AU - Yazdanpanah, Yazdan AU - Caumes, Eric AU - Fréchet-Jachym, Mathilde TI - Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis AID - 10.1183/13993003.01799-2016 DP - 2017 Mar 01 TA - European Respiratory Journal PG - 1601799 VI - 49 IP - 3 4099 - http://erj.ersjournals.com/content/49/3/1601799.short 4100 - http://erj.ersjournals.com/content/49/3/1601799.full SO - Eur Respir J2017 Mar 01; 49 AB - Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis (MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients treated with this drug outside clinical trials.All MDR-TB patients who started treatment from January 1, 2011 to December 31, 2013 and received ≥30 days of bedaquiline were included in a multicentre observational cohort.Among 45 MDR-TB patients, 53% harboured isolates resistant to both fluoroquinolones and second-line injectables, and 38% harboured isolates resistant to one of these drug classes. Median bedaquiline treatment duration was 361 days and 33 patients (73%) received prolonged (>190 days) bedaquiline treatment. Overall, 36 patients (80%) had favourable outcome, five were lost to follow-up, three died, and one failed and acquired bedaquiline resistance. No cases of recurrence were reported. Severe and serious adverse events were recorded in 60% and 18% of patients, respectively. Values of Fridericia-corrected QT interval (QTcF) >500 ms were recorded in 11% of patients, but neither arrhythmias nor symptomatic cardiac side-effects occurred. Bedaquiline was discontinued in three patients following QTcF prolongation. No significant differences in outcomes or adverse events rates were observed between patients receiving standard and prolonged bedaquiline treatment.Bedaquiline-containing regimens achieved favourable outcomes in a large proportion of patients. Prolonged bedaquiline treatment was overall well tolerated in this cohort.Treatment regimens including prolonged bedaquiline use are effective and overall well tolerated in MDR-TB patients http://ow.ly/vhtl305CYJj